TY - JOUR
T1 - Comparative effectiveness of frame-based and mask-based Gamma Knife stereotactic radiosurgery in brain metastases
T2 - A 509 patient meta-analysis
AU - Pichardo-Rojas, Pavel S.
AU - Vázquez-Alva, Diego
AU - Alvarez-Castro, José A.
AU - Flores-Patiño, Brandon
AU - Escalante-Ordoñez, Enrique
AU - Haro-Adame, Julio A.
AU - Espinosa-Temaxte, Carlos E.
AU - Amsbaugh, Mark
AU - Blanco, Angel I.
AU - Trifiletti, Daniel M.
AU - Esquenazi, Yoshua
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/10
Y1 - 2024/10
N2 - Purpose: Stereotactic Radiosurgery (SRS) is the primary treatment for patients with limited numbers of small brain metastases. Head fixation is usually performed with framed-based (FB) fixation; however, mask-based (MB) fixation has emerged as a less invasive alternative. A comparative meta-analysis between both approaches has not been performed. Methods: Databases were searched until August 28th, 2023, to identify studies comparing MB and FB SRS in the treatment of brain metastases. Our outcomes of interest included local tumor control (LTC), radiation necrosis (RN), mortality, and treatment time (TT). Mean difference (MD), risk ratio (RR), and hazard ratio (HR) were used for statistical comparisons. Results: From 295 articles initially identified, six studies (1 clinical trial) involving 509 patients were included. LTC revealed comparable RR at 6-months (RR = 0.95[95%CI = 0.89–1.01], p = 0.12) and a marginal benefit in FB SRS at 1-year (RR = 0.87[95%CI = 0.78–0.96], p = 0.005). However, in oligometastases exclusively treated with single-fraction SRS, LTC was similar among groups (RR = 0.92 [95%CI = 0.89–1.0], p = 0.30). Similarly, in patients with oligometastases treated with single-fraction SRS, RN (HR = 1.69; 95%CI = 0.72–3.97, p = 0.22), TT (MD = -29.64; 95%CI = -80.38–21.10, p = 0.25), and mortality were similar among groups (RR = 0.62; 95%CI = 0.22–1.76, p = 0.37). Conclusion: Our findings suggest that FB and MB SRS, particularly oligometastases treated with single-fraction, are comparable in terms of LTC, RN, TT, and mortality. Further research is essential to draw definitive conclusions.
AB - Purpose: Stereotactic Radiosurgery (SRS) is the primary treatment for patients with limited numbers of small brain metastases. Head fixation is usually performed with framed-based (FB) fixation; however, mask-based (MB) fixation has emerged as a less invasive alternative. A comparative meta-analysis between both approaches has not been performed. Methods: Databases were searched until August 28th, 2023, to identify studies comparing MB and FB SRS in the treatment of brain metastases. Our outcomes of interest included local tumor control (LTC), radiation necrosis (RN), mortality, and treatment time (TT). Mean difference (MD), risk ratio (RR), and hazard ratio (HR) were used for statistical comparisons. Results: From 295 articles initially identified, six studies (1 clinical trial) involving 509 patients were included. LTC revealed comparable RR at 6-months (RR = 0.95[95%CI = 0.89–1.01], p = 0.12) and a marginal benefit in FB SRS at 1-year (RR = 0.87[95%CI = 0.78–0.96], p = 0.005). However, in oligometastases exclusively treated with single-fraction SRS, LTC was similar among groups (RR = 0.92 [95%CI = 0.89–1.0], p = 0.30). Similarly, in patients with oligometastases treated with single-fraction SRS, RN (HR = 1.69; 95%CI = 0.72–3.97, p = 0.22), TT (MD = -29.64; 95%CI = -80.38–21.10, p = 0.25), and mortality were similar among groups (RR = 0.62; 95%CI = 0.22–1.76, p = 0.37). Conclusion: Our findings suggest that FB and MB SRS, particularly oligometastases treated with single-fraction, are comparable in terms of LTC, RN, TT, and mortality. Further research is essential to draw definitive conclusions.
KW - Frame-based
KW - Local tumor control
KW - Mask-based
KW - Metastatic brain tumors
KW - Radiotherapy techniques
KW - Stereotactic radiosurgery
KW - Treatment efficacy
UR - http://www.scopus.com/inward/record.url?scp=85201421422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201421422&partnerID=8YFLogxK
U2 - 10.1007/s11060-024-04738-8
DO - 10.1007/s11060-024-04738-8
M3 - Article
C2 - 39153030
AN - SCOPUS:85201421422
SN - 0167-594X
VL - 170
SP - 53
EP - 66
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 1
ER -